MedElevator Войти в исследования
← Поиск публикаций

DOI 10.26508/lsa.202201479

Медицинская библиотека · Life science alliance · 2022

Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.

Abella Eugenia, Trigueros Macedonia, Pradenas Edwards, Muñoz-Lopez Francisco, Garcia-Pallarols Francesc, Ben Azaiz Ben Lahsen Randa, Trinité Benjamin, Urrea Victor, Marfil Silvia, Rovirosa Carla, Puig Teresa, Grau Eulàlia, Chamorro Anna, Toledo Ruth, Font Marta, Palacín Dolors, Lopez-Segui Francesc, Carrillo Jorge, Prat Nuria, Mateu Lourdes, Clotet Bonaventura, Blanco Julià, Massanella Marta, VAC-COV-GM-HMAR, KING Cohort Extension and CoronAVI@S studies

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

SARS-CoV-2 vaccination is the most effective strategy to protect individuals with haematologic malignancies against severe COVID-19, while eliciting limited vaccine responses. We characterized the humoral responses following 3 mo after mRNA-based vaccines in individuals at different plasma-cell disease stages: monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma on first-line therapy (MM), compared with a healthy population. Plasma samples from uninfected MM patients showed lower SARS-CoV-2-specific antibody levels and neutralization capacity compared with MGUS, SMM, and healthy individuals. Importantly, COVID-19 recovered MM individuals presented significantly higher plasma neutralization capacity compared with their uninfected counterparts, highlighting that hybrid immunity elicit stronger immunity even in this immunocompromised population. No differences in the vaccine-induced humoral responses were observed between uninfected MGUS, SMM and healthy individuals. In conclusion, MGUS and SMM patients could be SARS-CoV-2 vaccinated following the vaccine recommendations for the general population, whereas a tailored monitoring of the vaccine-induced immune responses should be considered in uninfected MM patients.

Для цитирования: Abella Eugenia, Trigueros Macedonia, Pradenas Edwards, Muñoz-Lopez Francisco, Garcia-Pallarols Francesc, Ben Azaiz Ben Lahsen Randa, Trinité Benjamin, Urrea Victor, Marfil Silvia, Rovirosa Carla, Puig Teresa, Grau Eulàlia, Chamorro Anna, Toledo Ruth, Font Marta, Palacín Dolors, Lopez-Segui Francesc, Carrillo Jorge, Prat Nuria, Mateu Lourdes, Clotet Bonaventura, Blanco Julià, Massanella Marta, VAC-COV-GM-HMAR, KING Cohort Extension and CoronAVI@S studies. Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.. Life science alliance. 2022. DOI: 10.26508/lsa.202201479.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.